查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1603576

軸型脊椎關節炎 (axSpA) 市場報告：2030 年趨勢、預測和競爭分析

Axial Spondyloarthritis (AXSPA) Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

中軸型脊椎關節炎 (axSpA) 的趨勢和預測

全球中軸型脊椎關節炎（axSpA）市場未來性，非類固醇消炎劑（NSAID）、糖皮質激素和抗風濕藥市場充滿機會。到 2030 年，全球中軸型脊椎關節炎 (axSpA) 市場預計將達到 96 億美元，2024 年至 2030 年複合年成長率為 6.5%。該市場的主要促進因素是人口迅速老化、脊椎關節炎盛行率增加以及製藥公司為開發有效治療方法而活性化的研發活動。

  • Lucintel 預測，按類型分類，僵直性脊椎炎(AS) 將在預測期內成長最快。
  • 按藥物類別分類，非類固醇消炎劑(NSAID) 預計成長最快，因為它們可以緩解術後疼痛，並且通常由醫生處方。
  • 從地區來看，由於認知的提高和盛行率的上升，預計北美在預測期內將經歷最高的成長。

中軸型脊椎關節炎 (axSpA) 市場的策略性成長機會

中軸型脊椎關節炎 (axSpA) 市場在各種應用中提供了多種策略性成長機會。識別和利用這些機會可以推動市場擴張和創新：

  • 兒科治療：開拓治療兒童腋窩脊椎炎的特定年齡配方，為滿足具有獨特需求的特殊患者群體提供了機會，最終擴大了市場。
  • 早期診斷與早期療育：先進的診斷工具能夠及早發現 axSpA，從而改善患者的治療效果並顯著降低長期醫療費用。
  • 獲得農村醫療保健：在農村和服務欠缺地區利用遠端醫療和行動醫療單位可以改善獲得 axSpA 治療的機會，並提高都市區衛生系統的有效性，我們可以縮小差距並縮小健康差距。
  • 老年病學：越來越多的老年人容易患上 axSpA 等肌肉骨骼疾病，這將增加對標靶治療的需求，並為老年病學提供新的機會。
  • COVID-19 後治療：解決 COVID-19 引起的長期肌肉骨骼併發症為 axSpA 治療提供了一個新的細分市場，在改善患者治療效果的同時提供成長潛力。

這些成長機會正在推動 axSpA 市場的創新和市場擴張。透過技術進步滿足患者的各種需求，市場可以實現持續成長。

中軸型脊椎關節炎（axSpA）市場促進因素與挑戰

中軸型脊椎關節炎 (axSpA) 市場受到各種技術、經濟和監管因素的影響。了解這些市場促進因素和挑戰對於利用市場的動態性質並取得財務成功至關重要。

axSpA 市場的關鍵促進因素是：

1.技術進步：先進診斷工具和數位健康技術等技術創新使 axSpA 治療更易於管理，並有助於市場成長。

2.2. axSpA 盛行率不斷增加：受 axSpA 影響的患者數量不斷增加，需要有效的治療方案，從而推動市場成長並刺激該領域的進一步創新。

3.人口老化：隨著世界人口老化，axSpA等肌肉骨骼疾病的盛行率不斷增加，增加了治療需求並促進了市場成長。

4. 政府措施：政府改善醫療基礎設施和增加 axSpA 治療機會的措施正在推動需求，特別是在新興國家。

5.加大研發投入：製藥公司和政府正在加大研發投入，帶動axSpA市場新治療方法和創新的發展。

axSpA 市場面臨的挑戰是：

1.治療成本高：先進治療方法（尤其是生物製藥）的高治療成本可能會限制患者獲得治療並阻礙市場成長。

2. 監管障礙：嚴格的監管要求和漫長的核准流程可能會減緩新治療方法的推出並影響市場成長。

3.市場競爭：學名藥和替代療法的激烈競爭給價格和市場佔有率帶來壓力，迫使主要企業不斷創新以維持自己的地位。

這些市場促進因素和挑戰塑造了市場動態。尋求在這一競爭格局中取得成功的公司必須了解這些因素，才能有效駕馭市場格局。

目錄

第1章執行摘要

第2章全球中軸型脊椎關節炎 (axSpA) 市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球中軸型脊椎關節炎（axSpA）市場趨勢（2018-2023）與預測（2024-2030）
  • 全球中軸型脊椎關節炎 (axSpA) 市場（按類型）
    • 僵直性脊椎炎（AS）
    • 非放射性中軸型脊椎關節炎 (nr-axSpA)
  • 全球中軸型脊椎關節炎 (axSpA) 市場（按藥物類別）
    • 非類固醇消炎劑(NSAID)
    • 糖皮質激素
    • 抗風濕藥
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 按地區分類的全球中軸型脊椎關節炎 (axSpA) 市場
  • 北美中軸型脊椎關節炎 (axSpA) 市場
  • 歐洲中軸型脊椎關節炎（axSpA）市場
  • 亞太地區中軸型脊椎關節炎 (axSpA) 市場
  • 其他地區中軸型脊椎關節炎（axSpA）市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按類型分類的全球中軸型脊椎關節炎 (axSpA) 市場成長機會
    • 按藥物類別分類的全球中軸型脊椎關節炎 (axSpA) 市場成長機會
    • 全球中軸型脊椎關節炎 (axSpA) 市場成長機會（按地區）
  • 全球中軸型脊椎關節炎 (axSpA) 市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球中軸型脊椎關節炎（axSpA）市場容量擴張
    • 全球中軸型脊椎關節炎 (axSpA) 市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Janssen Biotech
  • AbbVie
  • UCB
  • Amgen
  • Novartis Pharmaceuticals Corporation
簡介目錄

Axial Spondyloarthritis (AXSPA) Trends and Forecast

The future of the global axial spondyloarthritis (AXSPA) market looks promising with opportunities in the non-steroidal anti-inflammatory drug (NSAID), glucocorticoid, and anti-rheumatic drug markets. The global axial spondyloarthritis (AXSPA) market is expected to reach an estimated $9.6 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are a surge in the aging population, the rising prevalence of spondyloarthritis, and growing research and development activities by pharmaceutical companies to develop effective treatments.

  • Lucintel forecasts that, within the type category, ankylosing spondylitis (AS) is expected to witness higher growth over the forecast period.
  • Within the drug class category, non-steroidal anti-inflammatory drug (NSAIDs) is expected to witness the highest growth due to their help to relieve pain after surgery and are mostly prescribed by doctors.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to an increase in awareness and rising prevalence of disease.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Axial Spondyloarthritis (AXSPA) Market

Emerging trends in the axial spondyloarthritis (AxSpA) market are reshaping its future applications and dynamics:

  • Personalized Medicine: The adoption of personalized medicine in AxSpA is gaining popularity, guided by genomic testing, which leads to targeted therapies. This allows treatments to be tailored to individual profiles, reducing side effects and improving overall outcomes.
  • Biosimilars: The introduction and acceptance of biosimilars are increasing due to their lower cost compared to biologics. This makes treatments more accessible to a larger patient population, thereby contributing to market growth.
  • Digital Health Technologies: Digital health technologies, such as telemedicine and mobile health apps, are increasingly used in AxSpA management. These tools improve monitoring, enhance adherence to treatment plans, and provide real-time data to aid medical decision-making.
  • Combination Therapies: Combination therapies, which include several active components, are becoming more common in treating AxSpA. These formulations simplify treatment regimens, enhance patient compliance, and target multiple disease pathways, leading to improved therapeutic outcomes.
  • Patient-Centric Care: There is a growing shift toward holistic treatment approaches that focus on improving the overall quality of life for patients. Emphasis is being placed on patient education, lifestyle modifications, and comprehensive management plans that address both physical and mental health aspects.

These emerging trends are reshaping the AxSpA market, driving innovation and improving patient care. These trends will have a significant impact on market growth and direction as they continue to evolve.

Recent Developments in the Axial Spondyloarthritis (AXSPA) Market

Recent developments in the axial spondyloarthritis market include a range of innovations and advancements:

  • New Drug Approvals: The approval of new biologics and biosimilars for AxSpA is expanding the therapeutic options available to patients, leading to better treatment outcomes and improved quality of life.
  • Technological Innovations: Advancements such as improved diagnostic tools and digital health technologies are enhancing the detection and management of AxSpA, improving patient adherence to treatment regimens.
  • Strategic Collaborations: Collaborations between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development of novel therapeutics, leading to improved clinical outcomes through combined expertise and resources.
  • Regulatory Advancements: Regulatory advancements, including faster approval processes and incentives for orphan drug development, are encouraging innovation in the AxSpA market, enabling quicker access to cutting-edge treatments.
  • Increased R&D Investment: Rising research and development funding from both the private sector and governments is facilitating the discovery of new therapeutic targets and the development of advanced treatments for AxSpA.

These developments are significantly influencing the AxSpA market by fostering innovation, enhancing patient outcomes, and expanding treatment options. They will play a crucial role in the market's continued expansion.

Strategic Growth Opportunities for Axial Spondyloarthritis (AXSPA) Market

The axial spondyloarthritis (AxSpA) market presents several strategic growth opportunities across various applications. Identifying and capitalizing on these opportunities can drive market expansion and innovation:

  • Pediatric Treatment: Developing age-specific formulations for treating AxSpA in children offers an opportunity to address a special patient group with unique needs, ultimately expanding the market.
  • Early Diagnosis and Intervention: Advanced diagnostic tools enable earlier detection of AxSpA, leading to better patient outcomes and significant long-term healthcare cost savings.
  • Rural Healthcare Access: The use of telemedicine and mobile healthcare units in rural and underserved areas can improve access to AxSpA treatments, bridging the gap between urban and rural healthcare systems and reducing health disparities.
  • Geriatric Care: The increasing elderly population, who are more likely to develop musculoskeletal disorders like AxSpA, creates a growing demand for targeted treatments, offering new opportunities in geriatric care.
  • Post-COVID-19 Therapeutics: Addressing long-term musculoskeletal complications resulting from COVID-19 presents a new market segment for AxSpA treatments, offering the potential for growth while also improving patient outcomes.

These growth opportunities are driving innovation and market expansion in the AxSpA market. By meeting various patient needs through technological advancements, the market can achieve sustainable growth.

Axial Spondyloarthritis (AXSPA) Market Driver and Challenges

The axial spondyloarthritis (AxSpA) market is influenced by various technological, economic, and regulatory factors. Understanding these drivers and challenges is crucial for navigating the dynamic nature of the market and achieving financial success.

The key drivers of the AxSpA market include:

1. Technological Advancements: Technological innovations, such as advanced diagnostic tools and digital health technologies, improve the ease of managing AxSpA treatments, contributing to market growth.

2. Increasing Prevalence of AxSpA: The rising number of individuals affected by AxSpA necessitates effective treatment options, driving market growth and spurring further innovation in the field.

3. Aging Population: As the global population ages, the incidence of musculoskeletal disorders like AxSpA increases, leading to higher demand for treatments and contributing to market growth.

4. Government Initiatives: Particularly in emerging economies, government efforts to improve healthcare infrastructure and increase access to AxSpA treatments are pushing up demand.

5. Increased R&D Investment: Pharmaceutical companies and governments are investing more heavily in R&D, leading to the development of new treatments and innovations in the AxSpA market.

Challenges facing the AxSpA market include:

1. High Treatment Costs: The high cost of advanced therapies, particularly biologics, can limit patient access to treatment and hinder market growth.

2. Regulatory Hurdles: Stringent regulatory requirements and lengthy approval processes can slow the introduction of new treatments, impacting market growth.

3. Market Competition: Intense competition from generic drugs and alternative therapies can put pressure on prices and market share, compelling key players to continually innovate to maintain their position.

These drivers and challenges shape the market's dynamics. Companies seeking success in this competitive industry must understand these factors to effectively navigate the market landscape.

List of Axial Spondyloarthritis (AXSPA) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies axial spondyloarthritis (AXSPA) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the axial spondyloarthritis (AXSPA) companies profiled in this report include-

  • Janssen Biotech
  • AbbVie
  • UCB
  • Amgen
  • Novartis Pharmaceuticals Corporation

Axial Spondyloarthritis (AXSPA) by Segment

The study includes a forecast for the global axial spondyloarthritis (AXSPA) by type, drug class, and region.

Axial Spondyloarthritis (AXSPA) Market by Type [Analysis by Value from 2018 to 2030]:

  • Ankylosing Spondylitis (AS)
  • Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (AXSPA) Market by Drug Class [Analysis by Value from 2018 to 2030]:

  • Non-Steroidal Anti-Inflammatory Drugs (NSAID)
  • Glucocorticoids
  • Anti-Rheumatic Drugs
  • Others

Axial Spondyloarthritis (AXSPA) Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Axial Spondyloarthritis (AXSPA) Market

Major players in the AxSpA market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are recent developments from key regions: the USA, China, India, Japan, and Germany.

  • United States: The FDA has recently approved new biologics and biosimilars for AxSpA. There is also a growing focus on patient-centric approaches, incorporating advanced diagnostic tools that enhance early detection and enable personalized treatment plans. This has led to improved patient outcomes.
  • China: Investment in healthcare infrastructure and research in China has led to the development of advanced biologics and biosimilars for AxSpA. Government initiatives aimed at improving access to medical services have increased demand for these treatments across the population.
  • Germany: In Germany, AxSpA treatment is increasingly centered around personalized medicine, with the integration of advanced diagnostic technologies. Collaborative studies between academic institutions and pharmaceutical companies are facilitating the faster development of innovative therapies and improving clinical outcomes.
  • India: In India, cost-effective generics and biosimilars dominate the AxSpA market. Recent developments include growing awareness of AxSpA diagnosis and government initiatives aimed at improving healthcare accessibility and affordability.
  • Japan: Japan is leveraging its strong pharmaceutical infrastructure to develop next-generation biologics for AxSpA treatment. New therapies have been approved, and the integration of digital health technologies is improving patient care and management.

Features of the Global Axial Spondyloarthritis (AXSPA) Market

Market Size Estimates: Axial spondyloarthritis (axspa) market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Axial spondyloarthritis (axspa) market size by type, drug class, and region in terms of value ($B).

Regional Analysis: Axial spondyloarthritis (axspa) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, drug class, and regions for the axial spondyloarthritis (axspa) market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the axial spondyloarthritis (axspa) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the axial spondyloarthritis (axspa) market to 2030 by technology (thermal, night vision, laser rangefinder, digital storage, and others), stabilization (image stabilized and standard), application (military, astronomy, sports, hunting & shooting, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Axial Spondyloarthritis (AXSPA) Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Axial Spondyloarthritis (AXSPA) Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Axial Spondyloarthritis (AXSPA) Market by Type
    • 3.3.1: Ankylosing Spondylitis (AS)
    • 3.3.2: Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
  • 3.4: Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
    • 3.4.1: Non-Steroidal Anti-Inflammatory Drugs (NSAID)
    • 3.4.2: Glucocorticoids
    • 3.4.3: Anti-Rheumatic Drugs
    • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Axial Spondyloarthritis (AXSPA) Market by Region
  • 4.2: North American Axial Spondyloarthritis (AXSPA) Market
    • 4.2.1: North American Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.2.2: North American Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.3: European Axial Spondyloarthritis (AXSPA) Market
    • 4.3.1: European Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.3.2: European Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.4: APAC Axial Spondyloarthritis (AXSPA) Market
    • 4.4.1: APAC Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.4.2: APAC Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others
  • 4.5: ROW Axial Spondyloarthritis (AXSPA) Market
    • 4.5.1: ROW Market by Type: Ankylosing Spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
    • 4.5.2: ROW Market by Drug Class: Non-Steroidal Anti-Inflammatory Drugs (NSAID), Glucocorticoids, Anti-Rheumatic Drugs, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Type
    • 6.1.2: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Drug Class
    • 6.1.3: Growth Opportunities for the Global Axial Spondyloarthritis (AXSPA) Market by Region
  • 6.2: Emerging Trends in the Global Axial Spondyloarthritis (AXSPA) Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Axial Spondyloarthritis (AXSPA) Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Axial Spondyloarthritis (AXSPA) Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Janssen Biotech
  • 7.2: AbbVie
  • 7.3: UCB
  • 7.4: Amgen
  • 7.5: Novartis Pharmaceuticals Corporation